Nevena Vicic, MSc, discusses first real-world data showing mRNA-1283 protected adults 65 and older from COVID-19 hospitalization in 2025-2026.
The FDA approved talazoparib plus enzalutamide for HRR-mutated metastatic hormone-sensitive prostate cancer after TALAPRO-3 cut progression risk by 52%. In mHSPC, the cancer has spread outside the ...
Not every patient who carries Clostridioides difficile ( C diff) gets sick, and distinguishing colonization from true ...
Karolinska Institutet’s Antoine Créon, MD, explains how alert fatigue, workflow, and center-level variation may have limited ...
Naima T. Joseph, MD, MPH, discusses why measles immunity screening in pregnancy is debated and how vaccination and counseling ...
Jordan Feld, MD, MPH, discusses bepirovirsen's approval and how capsid assembly modulators and gene editing could lead to a true hepatitis B cure. It is the first therapy approved with a primary ...
Permanent standard time is the only option that ends biannual clock changes while keeping the body aligned with the sun, ...
As cancer treatments improve and patients are living longer, answering the question of who takes charge of care once active ...
The FDA on Friday approved a subcutaneous (SC) induction regimen for risankizumab-rzaa (Skyrizi; AbbVie) in adults with moderately to severely active Crohn disease, giving patients the option to begin ...
Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...
OneOncology's Larry Bilbrey outlines network-level contracting, data security, physician review of AI output, and clear ...
Two new approvals reshape the complicated UTI landscape within a single year: an intravenous option revived after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results